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Abstract 
Spinal muscular atrophy (SMA) is a neuromuscular disease caused by low levels of 
SMN protein, primarily affecting lower motor neurons.  Recent evidence from SMA 
and related conditions suggests that glial cells can influence disease severity.  Here, 
we investigated the role of glial cells in the peripheral nervous system by creating 
SMA mice selectively overexpressing SMN in myelinating Schwann cells (Smn
-/-
;SMN2
tg/0
;SMN1
SC
).  Restoration of SMN protein levels restricted solely to Schwann 
cells reversed myelination defects, significantly improved neuromuscular function 
and ameliorated neuromuscular junction pathology in SMA mice. However, 
restoration of SMN in Schwann cells had no impact on motor neuron soma loss from 
the spinal cord or ongoing systemic and peripheral pathology.  This study provides 
evidence for a defined, intrinsic contribution of glial cells to SMA disease 
pathogenesis and suggests that therapies designed to include Schwann cells in their 
target tissues are likely to be required in order to rescue myelination defects and 
associated disease symptoms.  
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Introduction   
Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular 
condition, with an incidence of ~1 in 6000 - 11000 live births (1, 2).  The major 
pathological characteristic of SMA is a loss of lower alpha motor neurons from the 
ventral horn of the spinal cord, resulting in progressive muscle atrophy and eventual 
paralysis.  SMA is primarily caused by homozygous deletion of, or mutations in, the 
survival of motor neuron 1 (SMN1) gene (3).  Its full-length protein product, SMN, is 
a ubiquitous and essential cellular protein.  In humans, there are two SMN genes, 
SMN1 and SMN2 (4).  However, a base pair substitution in SMN2 results in increased 
exclusion of exon 7 from transcripts and production of an unstable transcript (5, 6).  
SMN2 therefore produces considerably less full-length SMN protein than SMN1 and 
cannot fully compensate for its loss (4). 
 
Motor neurons are particularly vulnerable to low levels of SMN (4). However, with 
the emergence of SMA animal models and a clearer appreciation of disease pathology 
in human patients, it has become apparent that reduced levels of SMN have additional 
effects on multiple other cell-types and tissues (7).  For example, skeletal muscle cells 
in cultures from severe SMA patients show defective development and are 
disorganized (8, 9); cardiac arrhythmias and abnormalities are one of the most 
common peripheral phenotypes reported in patients with severe SMA (10); while 
vascular (11-15), liver (16, 17), metabolic (18) and consistent intestinal and lung (13) 
abnormalities have also been reported. 
 
In addition, there is growing evidence from studies of related motor neuron diseases, 
such as amyotrophic lateral sclerosis (ALS), that non-neuronal cells can play a 
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defining role in regulating motor neuron degeneration (19).  This may have particular 
relevance for SMA in light of recent studies showing that restoration of SMN in 
motor neurons had only modest effects on the SMA phenotype (20-23). 
 
Evidence of gliosis in SMA patients has been known for some time (24-26) and 
recent work has suggested that astrocytes in particular may contribute to SMA 
pathogenesis in the central nervous system (CNS).  For example, morphological and 
cellular alterations in astrocytes occur prior to the loss of motor neurons (27).  Similar 
evidence for astrogliosis has been presented from post-mortem patient spinal cords 
(28).  Glial cells from the peripheral nervous system (PNS) have also been implicated 
in SMA, with changes observed in non-myelinating terminal Schwann cells in several 
different SMA mouse models (29-31). Similarly, in vivo and in vitro analyses of 
myelinating Schwann cells demonstrated intrinsic defects in SMA (evidenced by 
SMN-dependent failure of isolated SMA-derived Schwann  cells to respond to 
myelination cues), leading to defects in myelination and generation of extracellular 
matrix in peripheral nerve (32, 33).   
 
Despite accumulating evidence for intrinsic pathology of Schwann cells in SMA, it 
remains unknown whether Schwann cells directly influence motor neuron pathology. 
Answering this question will be important, not only to better understand the 
contribution of cell autonomous and non-cell autonomous pathways to motor neuron 
degeneration in SMA, but also to identify critical targets for delivering effective 
therapies for the treatment of SMA.  
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Results  
Generation of SMN1
SC
 transgenic mice.   
To determine the effect of restoring SMN selectively in myelinating Schwann cells, 
we generated a novel transgenic mouse line where  human SMN1 cDNA was placed 
under the control of a hybrid Mpz/P0-Cx32 construct known to drive efficient 
expression of transgenes in myelinating Schwann cells (34) (Figure 1A).  Mpz-driven 
constructs do not express in motor neurons, CNS glia, or non-myelinating peripheral 
nervous system (PNS) glia (e.g. terminal Schwann cells)(34). Mpz/P0-Cx32 -driven 
SMN1 constructs were microinjected into fertilised mouse oocyte to generate wild-
type transgenic mice expressing human SMN1 in myelinating Schwann cells 
(SMN1
SC
). To identify mice carrying the human SMN1 gene we developed a specific 
and sensitive qualitiative PCR assay that exclusively amplified SMN1 (Figures 1B and 
1C).  The primers did not amplify murine Smn (control 1, 2 and 3; Figure 1B) or the 
human SMN2 transgene (control 4; Figure 1B) and were capable of detecting at least 
one copy of human SMN1 (Figure 1C). Two SMN1
SC
 transgene-positive founders 
were generated (GO30 and GO40) from a total of 68 live pups.  A backcross of the 
GO40 founder mouse with an FVB/N mouse yielded  83 % transgene positive pups.  
A similar cross between the GO30 founder mouse and an FVB/N mouse generated no 
transgene positive pups. 
 
FLAG-SMN (1 kDa larger than SMN) was expressed in peripheral nerve, but not in a 
range of other tissues (muscle, brain, heart, liver and spinal cord) in the GO40 line, 
indicating that FLAG-SMN expression was indeed limited to the PNS, as expected 
(Figure 1D).  PNS expression was confirmed by immunohistochemical analyses of 
sectioned and teased nerve fibres from sciatic nerve; an antibody to the 5’ FLAG tag 
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on the transgene demonstrated clear expression of FLAG-SMN in sciatic nerve co-
stained with S100, a Schwann cell marker (Figure 1E).   
 
Over-expression of SMN in myelinating Schwann cells does not affect normal 
neuromuscular development  
Next, we wanted to confirm that overexpression of SMN in myelinating Schwann 
cells was not detrimental to normal neuromuscular development.  At the gross 
anatomical level, mice expressing SMN1
SC  
were indistinguishable from control 
animals, with similar survival (Figure 4H) and breeding rates (data not shown). We 
confirmed that SMN was significantly overexpressed in SMN1
SC
 positive control mice 
(control + SMN1
SC
) compared to wildtype mice (control) (~2000-fold) (Figures 2E 
and 2F).  To investigate potential effects at the cellular level, we carried out an 
assessment of intercostal nerves from P7 mice expressing the SMN1 transgene.  
Measurement of axon thickness and axon plus myelin thickness allows a G-ratio to be 
calculated.  G-ratio measurements enable assessment of myelin thickness with 
increased G-ratios indicating a reduction in average myelin sheath thickness relative 
to the axon diameter.  There was no qualitative or quantitative difference in myelin 
sheath thickness in mice expressing SMN1
SC 
(Figures 2A and 2B).  There was also no 
change in the number of non-myelinated large diameter (> 1 µm) axons (Figure 2C) 
or animal weight (Figure 2D). Thus, supra-physiological levels of SMN protein are 
well tolerated by Schwann cells, with no overt impact on normal peripheral nerve 
myelination. 
 
Following confirmation that the GO40 line expressed SMN as expected and that there 
were no detrimental effects due to overexpression of SMN in myelinating Schwann 
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cells, we backcrossed these mice onto a FVB/N background until 98.4 % 
homozygosity was reached.  Experimental ‘rescue’ animals (mice lacking 
endogeneous Smn1, heterozygous for SMN2 and expressing SMN1 in Schwann cells; 
Smn
-/-
;SMN2
tg/0
;SMN1
SC
 or SMA+SMN1
SC
) were then generated by crossing SMN1
SC
 
mice with the severe ‘Taiwanese’ SMA line (Smn
-/-
;SMN2
tg/tg
 or SMA) (34-36).  We 
confirmed that SMN was significantly overexpressed in SMN1
SC
 positive mice 
(~2000-fold in control + SMN1
SC
; ~3000-fold in SMA + SMN1
SC
 mice compared to 
non-SMN1
SC
 carrying control and SMA mice (Figures 2E and 2F). 
 
Restoration of SMN to myelinating Schwann cells rescues myelin sheath defects in 
SMA mice  
Previously, we reported that intercostal nerves from Taiwanese SMA mice had 
defective myelination, manifesting as a thinner myelin sheath and a larger number of 
large diameter unmyelinated axons at both mid- (P7) and late- (P11) symptomatic 
time points (33).  To evaluate whether restoration of SMN expression in myelinating 
Schwann cells was sufficient to ameliorate these myelin defects we assessed 
intercostal nerve myelination in experimental rescue mice (SMA+SMN1
SC
) at a 
mid/late-symptomatic time point (P7). Intercostal nerves were selected for these 
experiments due to the findings from previous results showing that the most robust 
myelination defects observed in Taiwanese SMA are to be found in intercostal nerves 
(e.g. compared to sciatic nerve) (33). 
 
Qualitatively, myelin thickness in SMA rescue mice appeared closer to that observed 
in control littermates than SMA mice (Figure 3A).  Quantitative analyses revealed a 
significant rescue of the myelin sheath pathology in SMA rescue mice with a 
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significantly reduced average G-ratio (0.656±0.007) compared to SMA mice 
(0.796±0.012), restored to levels observed in controls (0.670±0.009) (Figure 3C).  
Restoration of myelin thickness was observed across a full range of axonal calibres, 
with no evidence for reduced axon diameters in the SMA rescue mice (Figure 3D). In 
addition, there was a significant reduction in the number of non-myelinated large 
diameter (> 1 µm) axons in SMA rescue mice (Figure 3B).  
 
Taken together, these findings support the hypothesis that myelination defects in 
SMA result from direct, intrinsic deficiencies in Schwann cells, rather than occurring 
as a secondary consequence to pathology in neighbouring motor neurons (32, 33).  
 
Restoration of SMN to myelinating Schwann cells improves neuromuscular 
function and ameliorates neuromuscular junction pathology without affecting 
motor neuron soma loss or systemic pathology  
We next wanted to establish whether restoring SMN levels in Schwann cells could 
have any impact on neuromuscular function and/or motor neuron pathology.  Initial 
tests of neuromuscular function (using an established ‘righting test’ (37)) revealed 
that SMA rescue mice (SMA+SMN1
SC
) had a clear functional improvement at a 
mid/late-symptomatic time-point (P7) compared to SMA mice (Figure 4A). Although 
not maintained through to the end-stage of disease, SMA rescue mice also had 
modest, but significant, improvements in weight at P6, P7 and P8 (Figure 4B).   
 
Neuromuscular junction (NMJ) pathology is a major hallmark of motor neuron 
degeneration in SMA, with denervation and delayed motor endplate maturation being 
observed in many different mouse models of severe SMA (38, 39). However, in our 
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hands, the only robust NMJ pathology observed in the ‘Taiwanese’ mouse model of 
SMA is a reduced number of axonal inputs to NMJs, particularly notable in the 
levator auris longus (LAL) muscle (37). We therefore wanted to establish whether the 
improvements in neuromuscular function we observed in SMA rescue mice 
(SMA+SMN1
SC
) correlated with an amelioration of this aspect of NMJ pathology.  
We found a significant increase in the number of axonal inputs to NMJs in the LAL of 
SMA rescue mice, with the average number of inputs restored to levels observed in 
controls (P8/9; Figures 4C and 4D). Interestingly, these improvements in NMJ 
pathology occurred in the absence of any parallel improvement in skeletal muscle, 
with no rescue in the smaller muscle fibre diameters (from the LAL muscle) in the 
SMA rescue mice compared to SMA mice (P8/9; Figure 4E).  
 
Improvements in neuromuscular function and NMJ pathology observed in SMA 
rescue mice (SMA+SMN1
SC
) occurred in the absence of any significant improvement 
in levels of motor neuron soma loss from the ventral horn of spinal cord (Figure 4F 
and 4G). The number of motor neurons in the ventral horn of spinal cord was reduced 
by ~25% in SMA mice compared to controls, as previously reported (40). However, 
similar reduced numbers of motor neurons were also observed in the SMA rescue 
mice (SMA+SMN1
SC
). 
 
Previous reports have suggested that restoration of SMN solely in motor neurons 
improves motor neuron pathology, but only modestly influences systemic SMA 
pathology (20-23).  We therefore wanted to establish whether restoring SMN in 
myelinating Schwann cells, with concurrent improvements in myelination, 
neuromuscular function and NMJ pathology, resulted in any improvements in 
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systemic pathology.  Restoration of SMN in myelinating Schwann cells did not lead 
to any increase in survival or improvements in the gross appearance of SMA mice 
(Figure 4H, data not shown), indicating selective effects of targeting Schwann cells 
on glial/motor neuron pathology and resulting neuromuscular function.  
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Discussion 
In this study we have demonstrated that selective restoration of SMN in Schwann 
cells can lead to marked improvements in selective aspects of disease pathogenesis in 
a mouse model of severe SMA. Elevated levels of SMN in Schwann cells were well 
tolerated and did not influence normal Schwann cell or neuromuscular development. 
Restoring SMN in Schwann cells was sufficient to reverse the myelination defects 
that occur in SMA, suggesting that these occur due to an intrinsic defect in the glia 
cells, rather than as a secondary consequence of degenerative events occurring in 
neighbouring motor neurons. Alongside improvements in myelination, elevated levels 
of SMN in Schwann cells improved neuromuscular function and aspects of NMJ 
pathology. This indicates that at least some of the pathological changes and functional 
defects occurring in the neuromuscular system during severe forms of SMA are a 
consequence of defective glial cells. Whether such defects are also occurring in less 
severe forms of the disease needs to be established, and should be aided by the recent 
development of milder mouse models of SMA (e.g. SMN2B/- mice). 
 
One interesting observation made during the current study was that neuromuscular 
function and NMJ pathology were ameliorated in the absence of overt improvements 
in motor neuron loss or skeletal muscle fibre atrophy. This suggests that 
improvements in some aspects of neuromuscular pathology in SMA can be generated 
by interventions that do not directly target motor neurons and/or skeletal muscle.  
Thus, improving the health of myelinating Schwann cells alone would be predicted to 
have a significant impact on NMJ stability of neighbouring motor neurons, and also 
improve neuromuscular function in SMA patients (41).  The precise mechanisms 
through which Schwann cells can influence morphological and functional aspects of 
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neuromuscular connectivity in health and disease are only beginning to be uncovered.  
However, our findings in SMA are consistent with the recent demonstration that 
robust Schwann cell-motor neuron interactions are required in order to sculpt 
appropriate synaptic connectivity at the NMJ during development in neonatal mice 
(42).  
 
Our findings provide significant additional experimental support for a model whereby 
SMA represents a complex, multi-factorial disease, where disease symptoms cannot 
simply be ascribed to changes occurring solely in motor neurons and skeletal muscle 
fibres (7, 43). Thus, therapeutic targeting of motor neurons alone is unlikely to be 
sufficient to ameliorate all aspects of SMA disease pathogenesis.  For example, we 
previously reported significant amelioration of the neuromuscular phenotype, with no 
apparent influence on systemic pathology, in SMA mice following delivery of a β-
catenin inhibitor (37).  Moreover, viral gene therapy approaches used to restore SMN 
to astrocytes in the ∆7 model of SMA reported significant improvement in motor 
neuron-associated pathology, but again only produced a modest amelioration of 
systemic pathology and lifespan (28).  These findings are also in agreement with 
several studies that together suggest that restoration of SMN solely within motor 
neurons (returning SMN levels to those seen in wild-type healthy controls) leads to 
unexpectedly minor phenotypic improvements (20-23). Thus, therapies designed to 
restore SMN levels in human SMA patients would likely benefit from the ability to 
target Schwann cells (and other similar cell types) alongside motor neurons, if glial 
cell-associated defects are also to be successfully ameliorated. 
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In conclusion, whilst there is currently no cure for SMA, there is increasing evidence 
from pre-clinical trials that viral gene therapy approaches, and antisense 
oligonucleotide approaches can be both efficacious and translationally viable with 
respect to restoring SMN levels in vivo (44).  Our findings indicate that therapies 
capable of targeting SMN-dependent pathology in glial cells, alongside other critical 
disease targets such as motor neurons and skeletal muscle, are likely to be required in 
order to ameliorate the full range of neuromuscular pathology observed in SMA. 
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Materials and Methods 
pMPZ-SMN construct generation   
The pMpz-SMN1 transgene was created using a two-step cloning procedure from two 
starting plasmids: plasmid containing the full-length human SMN1 construct and the 
hybrid Mpz/P0-Cx32 construct that contains a 1.1 kb fragment containing the rat Mpz 
promoter fused to exons 1b and 2 and the intervening intron from the human Cx32 
gene (34) (Figure 1a).  Briefly, SMN1 was amplified using two overlapping forward 
primers that introduced NheI and AscI sites, an ATG start site and a 5’ FLAG tag (F1, 
5’–GCTAGCTAGCAGGCGCGCCATGGATTACAAGGATGACGACGATAAG-
3’; F2, 5’–AAGGATGACGACGATAAGGGAGGTGCGATGAGCAGCGGCGGC-
3’) and a reverse primer that introduced BglII and AatII sites and a TGA stop site  (R, 
5’-GGCTAAGATCTTGACGTCAATTTAAGGAATGTGAGCACCTTCC-3’).  
Amplifed products were digested using NheI and BglII (New England Biolabs),  
ligated to an intermediate plasmid (pGL4.13, Promega) using T4 DNA ligase 
(Promega), then confirmed by sequencing.  The intermediate SMN1-containing 
plasmid and the Mpz-promoter plasmid were digested using AscI and AatII (New 
England Biolabs) and ligated using T4 DNA ligase. pMpz-SMN1 constructs were 
confirmed by restriction digestion and sequencing. 
 
Pronuclear injection  
50 µg pMpz-SMN1 was digested with MluI and NotI (New England Biolabs), to 
release the 5.8 kb transgene cassette.  Transgenic injections were performed as 
previously described (45). 
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Genotyping of SMN1
SC
 transgene   
A PCR capable of detecting human SMN1 was optimized using a forward primer 
located in SMN1 exon 3 (5’- ACCACACCTAAAAGAAAACCTGCT-3’) and a 
reverse primer that spanned SMN1 exon 4 to exon 5 (5’- 
TTTCATTTTCATTCTCTTGAGCA-3’). 
 
Spiked PCR assay/transgene PCR standard   
To determine the sensitivity of the transgene genotyping reaction 200ηg genomic 
DNA (CD1 mice tail tip) was spiked with DNA from a plasmid expressing SMN1, 
p0Cx-SMN1, to generate a series of copy number standards; 0.1 copy (0.298ρg p0Cx-
SMN1); 1 copy (2.98ρg p0Cx-SMN1); 10 copies (29.8ρg p0Cx-SMN1); 50 copies 
(149ρg p0Cx-SMN1); 100 copies (298ρg p0Cx-SMN1). Amounts of DNA used were 
determined using a standard calculation [(mass of transgene DNA= (N bp transgene 
DNA x 1 µg genomic DNA)/3 x 10
9 
bp genomic DNA], assuming a haploid content 
of 3 x 10
9
 bp and hemizygosity of transgenic founder mice.   
 
SMA mice  
‘Taiwanese’ SMA mice (Smn
-/-
;SMN2
tg/tg
) (35)purchased from Jackson Labs on a 
congenic FVB/N background were maintained following an established breeding 
strategy (36) and had a mean survival of 10/11 days (d).  Litters were retrospectively 
genotyped using standard PCR protocols(35).  Mice expressing the transgene 
(SMN1
SC
) were backcrossed to wildtype FVB/N mice (Harlan Laboratories) for 4 
generations (93.75 % homozygosity).  A fifth generation backcross with FVB/N 
Smn
+/-
 mice generated pups with 96.87 % homozygosity (Smn
+/-
;SMN1
SC
).  A final 
backcross with ‘Taiwanese’ SMA mice (Smn
-/-
;SMN2
tg/tg
) generated four lines of 
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experimental animals; control (Smn
+/-
; SMN2
tg/0
), control mice expressing SMN1
SC
 
(Smn
+/-
; SMN2
tg/0
;SMN1
SC
), SMA mice (Smn
-/-
;SMN2
tg/0
), SMA mice expressing 
SMN1
SC
 (Smn
-/
-;SMN2
tg/0
;SMN1
SC
) (SMA rescue mice) (all > 98.4 % homozygosity).  
Litters from each backcross were genotyped at 14 d to determine SMN1
SC
 
transmission. All mice were housed within the animal care facilities in Edinburgh 
under standard SPF conditions.  All animal procedures and breeding were performed 
in accordance with Home Office and institutional guidelines.   
 
  
Immunohistochemical analysis of sectioned and teased nerve fibres   
Sciatic nerve was fixed in 4 % paraformaldehyde (PFA) for 30 min then washed in 
phosphate buffered saline (PBS).  Prior to sectioning, nerves were embedded 
longitudinally in a 1:1 solution of 30 % sucrose and OCT embedding matrix 
(CellPath).  10 µm sections were prepared on slides.  For nerve tease, the perineurium 
was carefully removed and fixed sciatic nerve fibres were teased in 0.1 Μ PBS on 3-
amino propyltriethoxysilane (TESPA) coated slides.  Slides were blocked for 0.5 hr 
with 5 % bovine serum albumin (BSA) and 0.2 % TritonX.  All nerves were 
incubated with primary antibodies raised against S100 (mouse, 1:100, Abcam) and 
FLAG (rabbit, 1:1000, ThermoFisher), then incubated in a solution of secondary 
antibodies (goat anti-mouse Alexa Fluor 555 and donkey anti-rabbit Alexa Fluor 488; 
both 1:500, Invitrogen).  Slides were coverslipped using Mowiol (Calbiochem) or 
FluorShield (Abcam).   
 
Non-quantitative and quantitative fluorescent western blotting   
Fresh tissue was dissected and frozen on dry ice and protein extracted in RIPA buffer 
(ThermoScientific) with protease inhibitor cocktail (Sigma).  Non-quantitative 
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western blots were performed using a primary antibody against SMN (mouse, 1:500; 
BD Transduction Laboratories).  Odyssey secondary antibodies were added according 
to the manufacturers’ instructions (goat anti-mouse IRDye 680).  Quantitative blots 
were carried out using a primary antibody against tubulin (mouse, 1:10000; Abcam).  
Blots were imaged using an Odyssey Infrared Imaging System (Li-COR, Biosciences) 
at a resolution of 169 µM.  Each blot was scanned and measured in triplicate to 
minimise user variability.  
 
Electron microscopy   
Intercostal nerves were incubated for 48 hr in 4 % PFA : 2.5 % glutaraldehyde at 4 
o
C 
before post-fixation in 1 % osmium tetroxide in 0.1 M phosphate buffer for 45 min. 
Following dehydration through an ascending series of ethanol solutions and propylene 
oxide, sections were embedded on glass slides in Durcupan resin.  Regions to be used 
for assessment of myelination were then cut out from a randomly selected section 
using a scalpel and glued onto a resin block for sectioning. Ultrathin sections (60 nm) 
were cut and collected on formvar-coated grids (Agar Scientific, UK), stained with 
uranyl acetate and lead citrate in an LKB Ultrostainer and then quantitatively assessed 
in a Philips CM12 transmission electron microscope equipped with a Gatan digital 
camera.  Intercostal nerve fibres were measured using ImageJ.  For each individual 
fibre, axon diameters and G ratios were calculated as previously described (46). 
 
Assessment of SMA rescue mice  
Righting reflex tests were performed to assess neuromuscular function, as previously 
described (37).  Mice were weighed daily and Kaplan-Meier survival analyses 
performed as previously described (21).  Muscle fibre diameter measurements were 
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taken from phase-contrast micrographs of teased muscle fibre preparations using 
ImageJ software (47). NMJ pathology was assessed on whole-mount preparations of 
levator auris longus (LAL) muscles (39).  Motor neuron cell body counts in the spinal 
cord were performed as previously described (40, 48).  
 
Microscopy 
Fluorescent images were captured using a Zeiss 710 laser-scanning confocal 
microscope (40× objective; 1.4NA) or a standard epi-fluorescence microscope 
equipped with a chilled CCD camera (20× or 40× objective; 0.8NA; Nikon IX71 
microscope; Hammamatsu C4742-95), as previously described (49).  
 
Statistical analysis   
All data were collected into Microsoft Excel and analysed using GraphPad Prism 
software (statistical tests used for each comparison are detailed in the text).  For all 
statistical analyses, p < 0.05 was considered statistically significant.  All data are 
expressed as mean ± SEM.  
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Legends to Figures  
Figure 1.  Restoration of SMN in myelinating Schwann cells.  (A) A pMpz-SMN, 
construct was generated by inserting the SMN1 gene downstream of the myelin 
protein zero (Mpz) promoter, incorporating a 5’ FLAG tag. (B) Oligonucleotides were 
designed to uniquely amplify the SMN1 gene demonstrated by amplification of 
SMN1
SC
 but not of endogenous mouse Smn1 [control 1 (Smn
+/-
, FVB), control 2 
(wildtype, FVB), control 3 (wildtype, CD1)] or human SMN2 [control 4 (Smn
-/-
:SMN2
tg/tg
)].  Negative sample (-).  (C) The amplification reaction had high sensitivity 
to the SMN1 transgene and was able to detect at least 1 copy of the pMpz-SMN1 
transgene [0.1, 0.1 copy p0Cx-SMN1 (0.298ρg p0Cx-SMN1); 1, 1 copy p0Cx-SMN1 
(2.98ρg p0Cx-SMN1); 10, 10 copies p0Cx-SMN1 (29.8ρg p0Cx-SMN1); 50, 50 copies 
p0Cx-SMN1 (149ρg p0Cx-SMN1); 100, 100 copies p0Cx-SMN1 (298ρg p0Cx-
SMN1);], control (wildtype, CD1), negative sample (-); 5µl total PCR product loaded 
per well.  (D) Representative immunoblot of tissue from Smn
+/+
;SMN1
SC 
mice 
demonstrating selective FLAG-SMN1 expression in peripheral nerve (sciatic nerve), 
but not in the central nervous system or systemic tissue.  Asterisk (*) indicates FLAG-
tagged SMN expressed from the pMpz-SMN construct;  25µg protein loaded per well.  
(E) Sectioned (left and middle panels) and teased sciatic nerve fibres (right panels) 
confirming expression of FLAG-SMN in peripheral nervous system of 
Smn
+/+
;SMN1
SC 
mice (SMN1
SC
), but not in Smn
+/+
 mice (control, FVB).  Scale bars = 
20µm (left and middle panels, E),  10µm (right panels, E). 
 
Figure 2.  Overexpression of SMN1 in Schwann cells is not detrimental.  (A) 
Representative electron micrograph of a large diameter myelinated axon from the 
intercostal nerve of a mouse expressing SMN1
SC
. (B) Intercostal nerves from control 
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mice expressing SMN
SC 
had no difference in G ratio measurements compared with
 
control mice (two-tailed, unpaired t-test; N = 3 mice per genotype, n > 50 independent 
nerve fibre measurements per genotype). (C) No significant increase in numbers of 
unmyelinated large diameter (> 1 µm) axons at P7 in control mice expressing SMN1
SC
 
(N = 3) (D) Restoration of SMN to Schwann cells had no detrimental effect on the 
weight of mice (N > 35 mice per genotype).  All tests two-tailed, unpaired t-tests; N = 
3 mice per genotype, n > 50 independent nerve fibre measurements per genotype. 
Scale bar  = 1 µm (A).  (E) Representative immunoblot of intercostal nerve tissue 
from control, transgenic control mice (control+SMN1
SC
), ‘Taiwanese” SMA mice 
(SMA) and SMA rescue mice (SMA+SMN1
SC
) demonstrating selective SMN1 
overexpression in mice carrying the pMpz-SMN construct. (F) SMN1 levels were 
normalized using tubulin levels as a loading control and demonstrated statistically 
significant SMN1 overexpression in mice carrying the pMpz-SMN construct.   
 
Figure 3.  Restoring SMN expression in Schwann cells rescues myelination 
defects in SMA mice. (A) Representative electron micrographs of large diameter 
(>1µm) myelinated axons in intercostal nerves from littermate control mice 
(control+SMN1
SC
), ‘Taiwanese” SMA mice (SMA), and SMA rescue mice 
(SMA+SMN1
SC
) at P7. (B) A significant rescue in numbers of unmyelinated large 
diameter (> 1 µm) axons in SMA rescue mice at P7. (C) A significantly lower average 
G-ratio in intercostal nerves from rescue SMA mice at P7 compared with ‘Taiwanese’ 
SMA mice (SMA), with higher G-ratios across the range of axon calibers (D). * P < 
0.05, **** P < 0.0001; all tests two-tailed, unpaired t-tests; N = 3 mice per genotype, 
n > 50 independent nerve fibre measurements per genotype.  Scale bar = 1.5 µm (A). 
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Figure 4. Restoring SMN expression in Schwann cells improves neuromuscular 
function and reverses NMJ pathology in SMA mice. (A) Significant improvement 
in time to right in mid/late-symptomatic (P7) SMA rescue mice (SMA+SMN1
SC
) 
compared to SMA littermates (P3, N = 18 mice control+SMN1
SC
; N = 35 SMA; N = 
19 SMA+SMN1
SC
; P7, N = 32 mice control+SMN1
SC
; N = 60 SMA; N = 33 
SMA+SMN1
SC
) (two-tailed, unpaired t-test). (B) Modest, but significant improvement 
in body weight in SMA rescue mice (N = 3 – 64 mice per genotype/time point; two-
tailed, unpaired t-test). (C/D) Reduced NMJ pathology (measured as the average 
number of axonal inputs per NMJ; multiply innervated NMJs are indicated by 
asterisks) in the levator auris longus (LAL) muscle of SMA rescue mice 
(SMA+SMN1
SC
) compared to SMA littermates at P8/9 (N = 3 mice, control+SMN1
SC
; 
N = 7 mice, SMA; N = 4 mice, SMA+SMN1
SC
; n > 50 NMJs per muscle) (two-tailed, 
unpaired t-test). (E) No amelioration of skeletal muscle fibre atrophy in the LAL 
muscle of SMA rescue mice at P8/9 compared to SMA littermates (N = 3 mice 
control+SMN1
SC
 and SMA; N = 4 SMA+SMN1
SC
; n = 50 measurements; two-tailed, 
unpaired t-test).  (F/G) No amelioration of motor neuron loss from the ventral horn of 
spinal cord in SMA rescue mice at P8/9 compared to SMA littermates (N = 3 mice 
control+SMN1
SC
 and SMA; N = 4 SMA+SMN1
SC
; n = 4; two-tailed, unpaired t-test). 
(H) No significant difference in survival of SMA rescue mice (N = 25 mice 
control+SMN1
SC
; N = 28 SMA; N = 15 SMA+SMN1
SC
) (Mantel-Cox test). * p < 
0.05,** p < 0.01, *** P < 0.001, **** P < 0.0001.  Scale bars = 20 µm (C) and 100 
µm (F). 
 
  
 at Edinburgh U
niversity on M
ay 19, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
  30
Abbreviations 
ALS: Amyotrophic lateral sclerosis 
CNS:  Central nervous system 
NMJ: Neuromuscular junction 
PNS: Peripheral nervous system 
SMA: Spinal muscular atrophy 
SMN:  Survival of motor neuron 
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